Daniel C. Adelman
2017 - Aimmune Therapeutics
In 2017, Daniel C. Adelman earned a total compensation of $1.7M as Chief Medical Officer at Aimmune Therapeutics, a 20% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $177,800 |
|---|---|
| Option Awards | $1,158,858 |
| Salary | $411,667 |
| Total | $1,748,325 |
Adelman received $1.2M in option awards, accounting for 66% of the total pay in 2017.
Adelman also received $177.8K in non-equity incentive plan and $411.7K in salary.
Rankings
In 2017, Daniel C. Adelman's compensation ranked 6,174th out of 14,666 executives tracked by ExecPay. In other words, Adelman earned more than 57.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,174 out of 14,666 | 58th |
Division Manufacturing | 2,266 out of 5,768 | 61st |
Major group Chemicals And Allied Products | 717 out of 2,074 | 65th |
Industry group Drugs | 554 out of 1,730 | 68th |
Industry Pharmaceutical Preparations | 436 out of 1,329 | 67th |
Source: SEC filing on April 11, 2018.
Adelman's colleagues
We found five more compensation records of executives who worked with Daniel C. Adelman at Aimmune Therapeutics in 2017.
2017
Stephen Dilly
Aimmune Therapeutics
Chief Executive Officer
2017
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
2017
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2017
Jeffrey Knapp
Aimmune Therapeutics
Chief Operating Officer
2017
Warren DeSouza
Aimmune Therapeutics